---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-036897"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:30:03.985472+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical posts record 2023 net sales of $83.6M; achieves first-ever adjusted EBITDA profit in Q4

## Summary
- Q4 2023 net sales $22.1M (+14% YoY); Q4 adjusted EBITDA $0.5M vs ($0.6M) in Q4 2022, first positive quarter in company history.
- Full-year 2023 net sales $83.6M (+15% YoY); gross profit $8.7M (+114% YoY); net loss improved 55% to ($8.4M).
- 2024 guidance: net product sales $84-88M (5-10% growth), gross margin 14-16%, and full-year adjusted EBITDA $0-0.5M.
- Amended Innovatus loan: interest rate reduced, maturity extended to Jan 2029; interest-only payments for 30-36 months.
- Acquired Evoqua hemodialysis concentrates assets in July 2023; became leading US liquid bicarbonate supplier.

## SEC filing metadata
- accession: 0001104659-24-036897
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000110465924036897/0001104659-24-036897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000110465924036897/tm249327d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-036897
- JSON: https://secwatch.observer/filing/0001104659-24-036897.json
- Plain text: https://secwatch.observer/filing/0001104659-24-036897.txt

## Key facts
- Earnings Releases
  ROCKWELL MEDICAL, INC. updated its the three months and twelve months ended December 31, 2023 guidance (initiated).
  - Period: the three months and twelve months ended December 31, 2023
  - Guidance: initiated
  - Result: reported results
  source text: Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide , today announced financial and operational results for the three months and twelve months ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000110465924036897/0001104659-24-036897-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.